| Title |
Benperidol for schizophrenia
|
|---|---|
| Published in |
Cochrane database of systematic reviews, April 2005
|
| DOI | 10.1002/14651858.cd003083.pub2 |
| Pubmed ID | |
| Authors |
Christian Schwarz, Benno Hartung, Stefan Leucht |
| Abstract |
Benperidol is a relatively old antipsychotic drug that has been marketed since 1966. It has been used in Germany for 30 years, but is also available in Belgium, Greece, Italy, the Netherlands and the UK. Benperidol is a butyrophenone antipsychotic, with the highest neuroleptic potency in terms of D2 receptor blockade. Those taking it are therefore reputed to be at high risk of extrapyramidal side effects, but benperidol's unusual profile may render it valuable to subgroups of people with schizophrenia. |
X Demographics
The data shown below were collected from the profiles of 6 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 2 | 33% |
| Denmark | 1 | 17% |
| United Kingdom | 1 | 17% |
| Unknown | 2 | 33% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 6 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 84 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 84 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 12 | 14% |
| Student > Bachelor | 9 | 11% |
| Researcher | 8 | 10% |
| Student > Postgraduate | 6 | 7% |
| Student > Ph. D. Student | 6 | 7% |
| Other | 21 | 25% |
| Unknown | 22 | 26% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 24 | 29% |
| Nursing and Health Professions | 10 | 12% |
| Psychology | 10 | 12% |
| Sports and Recreations | 2 | 2% |
| Biochemistry, Genetics and Molecular Biology | 2 | 2% |
| Other | 10 | 12% |
| Unknown | 26 | 31% |
Attention Score in Context
This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 31 May 2023.
All research outputs
#5,264,158
of 25,457,858 outputs
Outputs from Cochrane database of systematic reviews
#7,177
of 11,499 outputs
Outputs of similar age
#12,269
of 69,836 outputs
Outputs of similar age from Cochrane database of systematic reviews
#21
of 51 outputs
Altmetric has tracked 25,457,858 research outputs across all sources so far. Compared to these this one has done well and is in the 79th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 11,499 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 40.0. This one is in the 37th percentile – i.e., 37% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 69,836 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 82% of its contemporaries.
We're also able to compare this research output to 51 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 58% of its contemporaries.